Catalyst
Slingshot members are tracking this event:
Phase 3 data of AbbVie's(ABBV) Risankizumab in Psoriasis due by the end of 2017 due by the end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 26, 2017
Occurred Source:
https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iii Study, Risankizumab, Psoriasis
